HU203201B - Process for producing antitumoural pharmaceutical composition having synergetic effect - Google Patents

Process for producing antitumoural pharmaceutical composition having synergetic effect Download PDF

Info

Publication number
HU203201B
HU203201B HU865560A HU556086A HU203201B HU 203201 B HU203201 B HU 203201B HU 865560 A HU865560 A HU 865560A HU 556086 A HU556086 A HU 556086A HU 203201 B HU203201 B HU 203201B
Authority
HU
Hungary
Prior art keywords
hexadecylphosphocholine
optionally
weight
mixture
pharmaceutical composition
Prior art date
Application number
HU865560A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT44441A (en
Inventor
Hansjoerg Eibl
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of HUT44441A publication Critical patent/HUT44441A/hu
Publication of HU203201B publication Critical patent/HU203201B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
HU865560A 1985-12-04 1986-12-04 Process for producing antitumoural pharmaceutical composition having synergetic effect HU203201B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3542893 1985-12-04
DE3606631 1986-02-28
PCT/EP1986/000705 WO1987003480A2 (en) 1985-12-04 1986-12-04 Medicament with anti-tumoral action containing hexadecylphosphocholine

Publications (2)

Publication Number Publication Date
HUT44441A HUT44441A (en) 1988-03-28
HU203201B true HU203201B (en) 1991-06-28

Family

ID=25838509

Family Applications (2)

Application Number Title Priority Date Filing Date
HU865560A HU203201B (en) 1985-12-04 1986-12-04 Process for producing antitumoural pharmaceutical composition having synergetic effect
HU87831A HU208143B (en) 1985-12-04 1986-12-04 Process for producing synergetic antitumorous pharmaceutical compositions and phosphate derivatives used as their active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU87831A HU208143B (en) 1985-12-04 1986-12-04 Process for producing synergetic antitumorous pharmaceutical compositions and phosphate derivatives used as their active ingredient

Country Status (15)

Country Link
US (2) US4837023A (OSRAM)
EP (4) EP0248047B1 (OSRAM)
JP (2) JPH0637393B2 (OSRAM)
AT (2) ATE64529T1 (OSRAM)
CA (2) CA1280369C (OSRAM)
DE (4) DE3641491A1 (OSRAM)
DK (2) DK172954B1 (OSRAM)
ES (2) ES2032755T3 (OSRAM)
FI (2) FI873363A0 (OSRAM)
GR (2) GR3002487T3 (OSRAM)
HU (2) HU203201B (OSRAM)
IE (2) IE59777B1 (OSRAM)
NO (2) NO175620C (OSRAM)
PT (2) PT83872B (OSRAM)
WO (2) WO1987003478A2 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5182271A (en) * 1989-08-10 1993-01-26 Sandoz Ltd. Thioether, keto-ester and alkyl phospholipids useful in treating multiple sclerosis
EP0412941B1 (en) * 1989-08-10 1996-05-15 Sandoz Ltd. Phospholipids for the treatment of multiple sclerosis
EP0419998A3 (en) * 1989-09-27 1991-10-23 Asta Pharma Aktiengesellschaft Use of alkylphosphonic acid derivatives for the treatment of psoriasis
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5506217A (en) * 1991-04-25 1996-04-09 The University Of British Columbia Phosphonates as anti-cancer agents
SG47844A1 (en) * 1991-07-04 1998-04-17 Asta Medica Ag A process for the preparation of alkylphosphocholines and the production thereof in pure form
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4235911A1 (de) * 1992-10-23 1994-04-28 Asta Medica Ag Stabilisierte Hexadecylphosphocholinlösungen in Glycerinalkylethern
WO1994028908A2 (en) * 1993-06-10 1994-12-22 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
CN1132586C (zh) 1993-09-09 2003-12-31 罗拉斯医疗公司 来自胆汁的免疫调节组合物、其制备方法及其用途
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
EP0781138B1 (en) * 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
WO1996024598A1 (en) * 1995-02-10 1996-08-15 The University Of British Columbia [4-hexadecyl-3-methoxy-butyl] phosphonic acid and its protein conjugates useful as anti-cancer agents
KR19980703088A (ko) 1995-03-16 1998-09-05 라카일레 지, 필리페 신규의 침전탄산칼슘 안료를 포함하는 잉크젯 기록지
KR100499190B1 (ko) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 육모제
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) * 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US7582678B2 (en) * 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
PL189654B1 (pl) * 1998-01-22 2005-09-30 Zentaris Gmbh Zastosowanie miltefosyny do wytwarzania leków
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
WO2002096826A2 (en) * 2001-05-29 2002-12-05 Koninklijke Philips Electronics N.V. Metal-ceramic bond
KR100871648B1 (ko) * 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
BR0215680A (pt) * 2002-04-26 2005-02-01 Rudolf Perl Composição farmacêutica oral estável
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
UY30042A1 (es) 2005-12-19 2007-07-31 Zentaris Gmbh Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
US8637688B2 (en) * 2006-12-20 2014-01-28 Julia Diederichs Topical dosage form comprising tri-substituted glycerol compounds
JP2011057647A (ja) * 2009-09-14 2011-03-24 Adeka Corp 化粧料
CA2840272C (en) 2011-06-24 2020-09-15 Glycoregimmune, Inc. Prevention and treatment of inflammatory conditions
CN102491994B (zh) * 2011-12-07 2014-10-15 宁波九胜创新医药科技有限公司 一种胆碱磷酸烷基酯的制备方法
WO2016094226A1 (en) * 2014-12-09 2016-06-16 Glycoregimmune, Inc. Prevention and treatment of inflammatory conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225227A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Derivate des n.n-bis-(2-chlor-aethyl)-phosphorsaeureamids
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
JPS60184092A (ja) 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法

Also Published As

Publication number Publication date
IE59777B1 (en) 1994-04-06
CA1280369C (en) 1991-02-19
WO1987003478A2 (en) 1987-06-18
EP0225608A3 (de) 1987-10-28
US5049552A (en) 1991-09-17
HUT44441A (en) 1988-03-28
EP0248047A1 (de) 1987-12-09
EP0248062A1 (de) 1987-12-09
EP0230575A2 (de) 1987-08-05
FI873364A0 (fi) 1987-08-03
HU208143B (en) 1993-08-30
US4837023A (en) 1989-06-06
PT83872B (pt) 1989-01-17
FI873363A7 (fi) 1987-08-03
ES2038215T3 (es) 1993-07-16
JPH0859677A (ja) 1996-03-05
GR3005168T3 (OSRAM) 1993-05-24
CA1338627C (en) 1996-10-01
DK398587D0 (da) 1987-07-30
NO873243D0 (no) 1987-08-03
DK393187D0 (da) 1987-07-28
NO873244D0 (no) 1987-08-03
EP0225608A2 (de) 1987-06-16
NO175620C (no) 1994-11-09
NO873244L (no) 1987-10-01
FI873363L (fi) 1987-08-03
ATE64529T1 (de) 1991-07-15
IE863176L (en) 1987-06-04
NO174877B (no) 1994-04-18
HUT44431A (en) 1988-03-28
FI873363A0 (fi) 1987-08-03
DE3641491A1 (de) 1987-09-17
PT83873B (pt) 1989-01-17
GR3002487T3 (en) 1992-12-30
WO1987003480A3 (en) 1988-02-25
DE3641379A1 (de) 1987-09-03
EP0248047B1 (de) 1991-06-19
PT83873A (de) 1987-01-01
DK393187A (da) 1987-07-28
WO1987003478A3 (en) 1987-09-24
PT83872A (de) 1987-01-01
ATE75608T1 (de) 1992-05-15
NO175620B (OSRAM) 1994-08-01
NO174877C (no) 1994-07-27
IE59778B1 (en) 1994-04-06
JPS63501719A (ja) 1988-07-14
JP2857084B2 (ja) 1999-02-10
EP0230575A3 (de) 1987-12-02
WO1987003480A2 (en) 1987-06-18
NO873243L (no) 1987-10-02
DE19375061I2 (de) 2008-11-20
ES2032755T3 (es) 1993-03-01
EP0248062B1 (de) 1992-05-06
DK398587A (da) 1987-07-30
JPH0637393B2 (ja) 1994-05-18
DE3679908D1 (de) 1991-07-25
IE863177L (en) 1987-06-04
DK172954B1 (da) 1999-10-18
FI873364A7 (fi) 1987-08-03

Similar Documents

Publication Publication Date Title
HU203201B (en) Process for producing antitumoural pharmaceutical composition having synergetic effect
DE69232101T2 (de) Lipid-derivate von phosphonsäuren für liposomale inkorporation und verwendungsverfahren
US5578631A (en) Methods of combating Pneumocystis carinii pneumonia and compounds useful therefor
JP3074733B2 (ja) 脂肪乳剤
US4826830A (en) Topical application of glyciphosphoramide
EP1477166B1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
Brugarolas et al. Treatment of cancer by an inducer of reverse transformation
NZ286207A (en) Formulation base comprising a polyoxyethylene/polyoxypropylene block copolymer, ethanol and water, optionally phospholipids and water soluble excipients; for use in nanosuspensions
EP1140017B1 (en) Water-insoluble drug delivery system
KR19980703828A (ko) 암 성장 억제용, 벤즈이미다졸 함유 약학 조성물
KR19980703829A (ko) 바이러스 및 암 성장 억제용, 엔-클로로페닐카르바메이트및 엔-클로로페닐티오카르바메이트 함유 약학 조성물
DE69104362T2 (de) Autobiotika sowie deren verwendung bei der in vivo eliminierung körperfremder zellen.
KR20130118733A (ko) 피하 지방분해에 의한 피하 지방 축적물의 제거를 위한 인지질 함유 조성물의 용도
KR20000036210A (ko) 장쇄 알코올, 알칸, 지방산 및 아미드로 바이러스를 억제하는 방법
JP2003516348A (ja) がん治療のための細胞増殖抑制剤及び電子受容体を含有する医薬製剤
WO2006076376A1 (en) Topical treatment of solid tumors and ocular neovascularization
EP1291340B1 (en) Phytosphingosine derivatives with antitumor activity
EP0448029A2 (en) Novel pharmaceutical uses of forskolin derivatives
KR100514009B1 (ko) 1,2,4-벤조트리아진옥사이드제제
US6538032B1 (en) Phytosphingosine derivatives with antitumor activity
KR100423102B1 (ko) 항암활성을 가지는 파이토스핑고신 유도체
EP0121856A2 (de) Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung
KR920008159B1 (ko) 생리활성 플라보노이드 리포좀의 제조방법
EP0260606A2 (en) Medicament for curing neurotic disturbance or disorder comprising sialocylglycerolipid
US20020173489A1 (en) Compositions containing a mixture of phosphorous compounds and alkylglycerols